PedAM
Pediatric Disease Annotations & Medicines
| Disease | astrocytoma |
| Phenotype | C0041341|tuberous sclerosis complex |
| Sentences | 34 |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 22654497 | Aggressive retinal astrocytoma associated with tuberous sclerosis complex is a rare variant of this usually benign astrocytoma, and the tumor enlarges progressively, leading to complications, including exudative retinal detachment, vitreous hemorrhage, and neovascular glaucoma.1,2 it has been reported that aggressive retinal astrocytoma can be treated with laser photocoagulation, photodynamic therapy, or intravitreal bevacizumab injection.2–7 herein, we report the case of a patient with aggressive retinal astrocytoma and macular edema who was initially treated with intravitreal bevacizumab injection. |
| PubMedID- 24667738 | This analysis focuses on the clinical presentation, management, and associated burden of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex in the united states. |
| PubMedID- 23686401 | Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 23229407 | Neuro-oncology: everolimus for astrocytoma in tuberous sclerosis complex. |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 23489586 | Currently, the food and drug administration (fda) has approved cci-779 for the treatment of advanced renal cell carcinoma, and rad001 for the treatment of advanced renal cell carcinoma, subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc), progressive neuroendocrine tumors of pancreatic origin, and postmenopausal women with advanced hormone-receptor-positive, her2-negative breast cancer (in combination with exemestane). |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 25456370 | Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised exist-1 study. |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 20643042 | [subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 25557360 | Background: the aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mtor) inhibitor, of subependymal giant cell astrocytomas (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 23231513 | Everolimus (rad001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 23138436 | The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles. |
| PubMedID- 25493579 | [subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors]. |
| PubMedID- 24105488 | We review the timing and use of surgery versus pharmacotherapy for the treatment of subependymal giant cell astrocytoma in patients with tuberous sclerosis complex. |
| PubMedID- 24667713 | Everolimus has demonstrated substantial clinical benefit in randomized, controlled, phase iii studies leading to approval for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, renal angiomyolipoma and subependymal giant-cell astrocytoma associated with tuberous sclerosis complex, as well as advanced hormone-receptor-positive (hr(+)) and human epidermal growth factor receptor-2-negative advanced breast cancer. |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 26248290 | Another report using everolimus as a treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex for approximately 3 years found the most frequent adverse events were also aphthous stomatitis and respiratory infections in children under 3 years of age, and no significant neuropsychological changes were noticed between baseline and follow-up [22]. |
| PubMedID- 23612453 | Everolimus is an oral mtor inhibitor currently approved in various countries for treatment-refractory advanced renal cell carcinoma; progressive, unresectable, advanced pancreatic neuroendocrine tumours; and renal angiomyolipoma and subependymal giant-cell astrocytomas associated with tuberous sclerosis complex. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
| PubMedID- 23158522 | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): a multicentre, randomised, placebo-controlled phase 3 trial. |
| PubMedID- 23158521 | Everolimus for astrocytomas in tuberous sclerosis complex. |
| PubMedID- 21047224 | Background: neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24319280 | Objective: this study was aimed to explore parents' experience of assisting children affected by tuberous sclerosis complex (tsc) with subependymal giant-cell astrocytoma (sega) manifestation, in order to understand their caring needs and expectation of support. |
| PubMedID- 24757527 | Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
Page: 1